Modest Changes in Practice for High-Sensitivity TnT Reporting

This article originally appeared here.
Share this content:
Modest Changes in Practice for High-Sensitivity TnT Reporting
Modest Changes in Practice for High-Sensitivity TnT Reporting

WEDNESDAY, Aug. 10, 2016 (HealthDay News) -- For patients presenting to the emergency department with chest pain, high-sensitivity troponin T (hs-TnT) reporting is associated with modest changes in practice, according to a study published online Aug. 9 in Circulation: Cardiovascular Quality and Outcomes.

Derek P. Chew, M.B.B.S., M.P.H., from Flinders University in Adelaide, Australia, and colleagues examined the impact of hs-TnT reporting on care and outcome among patients presenting to emergency departments with chest pain. A total of 1,937 patients without ST-segment elevation were enrolled and randomized to hs-TnT reporting (hs-report) or standard reporting (std-report).

The researchers found that 75.7 percent of patients had maximal troponin <30 ng/L within 24 hours. The admission rate was not altered with randomization to hs-report format (hs-report: 57.7 percent versus std-report: 58.0 percent; P = 0.069). There was no between-group difference in angiography (hs-report: 11.9 percent versus std-report: 10.9 percent; P = 0.479). There was no reduction in 12-month death or new-recurrent acute coronary syndrome in the overall population with hs-report (hs-report: 9.7 percent versus std-report: 7.2 percent; P = 0.362). There was a modest reduction in the primary end point among those with troponin levels <30 ng/mL (hs-report: 2.6 percent versus std-report: 4.4 percent; P = 0.050).

"High-sensitivity troponin reporting alone is associated with only modest changes in practice," the authors write. "Clinical effectiveness in the adoption of high-sensitivity troponin may require close coupling with protocols that guide interpretation and care."

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

Artificial Intelligence Promising for CA, Retinopathy Diagnoses

Artificial Intelligence Promising for CA, Retinopathy Diagnoses

Two studies evaluate use; one for breast cancer, the other for diabetic retinopathy

USPSTF Recommends Against Hormone Tx Post Menopause

USPSTF Recommends Against Hormone Tx Post Menopause

Benefits do not outweigh harms of using hormone therapy for prevention of chronic conditions

Omalizumab Ups Efficacy of Multifood Oral Immunotherapy

Omalizumab Ups Efficacy of Multifood Oral Immunotherapy

Findings in multifood allergic pediatric patients

is free, fast, and customized just for you!

Already a member?

Sign In Now »